Connect with us
[bsa_pro_ad_space id=12]

Business

From ‘brilliant’ to ‘aghast’: Reactions to RFK Jr.’s nomination for HHS secretary run the gamut

Published

12 minute read

From LifeSiteNews

By Dr. Brenda Baletti, The Defender

From “brilliant” to “aghast” – President-elect Donald J. Trump’s nomination on Thursday of Robert F. Kennedy Jr., founder of Children’s Health Defense (CHD), to run the U.S. Department of Health and Human Services (HHS) triggered a range of reactions among media outlets, public health officials, and Kennedy’s long-time supporters and detractors.

In a statement posted on Truth Social and X, Trump said Kennedy would restore the public health agencies “to the traditions of Gold Standard Scientific Research, and beacons of Transparency, to end the Chronic Disease epidemic, and to Make America Great and Healthy Again!”

Kennedy, who promised to fight corruption and end the revolving door between industry and government, thanked Trump for the nomination on social media. He said he would “free the agencies from the smothering cloud of corporate capture so they can pursue their mission to make Americans once again the healthiest people on Earth.”

 

Kennedy is a longtime critic of how corporate interests have captured the public health agencies meant to regulate them, and of the outsized and corrupt role that Big Pharma plays in American life.

If confirmed, Kennedy would hold the most powerful governmental position in public health, overseeing 80,000 employees across a department that houses 13 agencies and more than 100 programs. Those agencies include the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), the National Institutes of Health and the Center for Medicaid and Medicare Services.

CHD CEO Mary Holland told The Defender the organization “could not be more pleased” with the nomination, adding:

Kennedy has been devoted to ending the childhood chronic health epidemic for almost 20 years. He has been effective in communicating the failures of our existing public health establishment.

Based on his extensive litigation history, he is uniquely prepared to reform the regulatory institutions, the research institutions, and public education on health. I look forward to seeing dramatic, measurable improvements in Americans’ health during the Trump administration.

Democratic Colorado Gov. Jared Polis said on X that he was “excited by the news,” particularly about Kennedy’s commitment to fighting chemicals in foods, the power of Big Pharma, and to other health priorities.

“I hope he leans into personal choice on vaccines rather than bans (which I think are terrible, just like mandates) but what I’m most optimistic about is taking on big pharma and the corporate ag oligopoly to improve our health,” he added.

Rep. Chip Roy (R-Texas) told Fox News, “I think Robert is another disruptor. We need a disruptor. I will be glad and I’m looking forward to working with him,” Politico reported.

Sen. Ron Johnson (R-Wis.) called Kennedy a “brilliant, courageous truth-teller” and said he could make the “most significant impact on health.”

Vaccine stocks take a dive on news of announcement

On the flip side, some lawmakers and public health leaders expressed alarm, decrying the nomination.

U.S. Rep. Robert Garcia (D-Calif.) called the choice “f— insane” on X, Fox News reported. “He’s a vaccine denier and a tin foil hat conspiracy theorist. He will destroy our public health infrastructure and our vaccine distribution systems. This is going to cost lives.”

Dr. Richard E. Besser, CEO of the Robert Wood Johnson Foundation and a former acting director of the CDC, said that having Kennedy head up HHS “would pose incredible risks to the health of the nation,” because Kennedy’s critique of the public health agencies was worsening the mistrust lingering after the coronavirus pandemic, The New York Times reported.

Besser told CNN that some of Kennedy’s ideas about chronic health issues regarding children were good ideas, but other ideas were deeply concerning – particularly Kennedy’s proposal that individuals should decide for themselves whether to take a vaccine.

“The idea that receiving childhood vaccines would be a parental choice scares me,” he said.

READ: Canada’s public health agency still working to adopt WHO pandemic treaty: report

Current CDC Director Mandy Cohen raised concerns that Kennedy would use the position to spread misinformation and foster distrust in public health institutions, particularly with respect to vaccines.

Kennedy has called for an end to immunity for vaccine manufacturers for the injuries caused by their products. He points out that no vaccine on the childhood immunization schedule has undergone proper safety and efficacy testing.

He has been a long-term advocate for the tens of thousands of families seeking compensation for their children’s vaccine-induced autism.

Kennedy also promised that, if confirmed, he would make the V-safe vaccine injury data collected but not made public by the CDC transparent, so scientists have access to the data necessary to analyze vaccine safety

Vaccine and Pharma stocks fell sharply this morning, following yesterday’s announcement about Kennedy, Reuters reported.

 

Bavarian Nordic, which makes the mpox vaccine, was down 16 percent. Its CEO told Reuters he was concerned that Kennedy could fuel vaccine skepticism.

However, he also said that the U.S. response to the COVID-19 pandemic under Trump’s first term made him confident that the incoming administration would continue to fund biodefense.

The Trump administration launched and oversaw Operation Warp Speed, the public-private partnership to rapidly develop a COVID-19 vaccine that gave vaccine makers hundreds of billions in profits along with total immunity for any harms caused by those investigational vaccines under the Public Readiness and Emergency Preparedness (PREP) Act.

Kennedy will be ‘single greatest threat to profits in America’

Republican advisers have cautioned that Kennedy could face a difficult path to confirmation, The Washington Post reported, citing his “past statements on drugs and vaccines, and his many personal entanglements.” FiercePharma said his confirmation process is likely “to be contentious.”

Physician, professor and Substacker Dr. Vinay Prasad wrote that Trump could use a recess appointment to secure Kennedy’s position, but that he will likely need to be confirmed by the Senate where “He has a several hundred billion dollar industry that will do everything possible to stop him.”

“Many of these companies have lobbied throughout Congress,” Prasad added. “They will use those connections. Unlike other controversial appointees, RFK Jr. will be the single greatest threat to profits in America.”

If his appointment goes through, Prasad said Kennedy will face a difficult road in getting his proposed policies enacted, given the entrenched power of Pharma and the power of the media that opposes him.

Law professor Wendy Parmet, director of Northeastern University’s Center for Health Policy and Law, pointed to the potential clash between Kennedy’s anti-industry position and the big-business leanings of the Republican Party.

“We have an administration that promises to deregulate, to be business-friendly, and then we have RFK Jr., who promises to go after fast food,” Parmet told The Washington Post.

READ: Idaho health district votes to stop offering COVID vaccines at its medical centers

Health and health freedom advocates optimistic Kennedy will bring change

Despite the challenges ahead, health advocates are optimistic that changes they have been seeking for decades will come to pass.

During the COVID-19 pandemic, critics of pandemic policies were condemned and marginalized. Kennedy was censored by the Biden administration and social media companies as part of the so-called “Disinformation Dozen” for airing many of those critiques.

Over the course of the election Kennedy – who ran for president as a Democrat, then announced he was running as an independent before suspending his campaign and endorsing Trump – has repeatedly been called a “conspiracy theorist.” Both Kennedy and CHD are routinely dismissed as “anti-vax” for openly discussing the scientific evidence on the link between vaccines and chronic diseases including autism, attention-deficit/hyperactivity disorder or ADHD and other neuropsychiatric and autoimmune disorders, in some children.

Rather than investigating the science, mainstream media mostly insists these links have been “debunked,” without providing any evidence for their claim.

Kennedy has also called for the removal of fluoride from public drinking water, citing recent studies and a landmark federal court decision that show it interferes with children’s brain development – a concern that has even been flagged by some mainstream public health commentators.

His supporters hope these issues will now receive serious public attention that will lead to policy change.

Holland said on X that Kennedy’s nomination came 38 years to the day after the Vaccine Injury Act that gave vaccine manufacturers immunity from liability was signed into law.

Let’s rewrite this one,” she said.

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

Business

What Pelosi “earned” after 37 years in power will shock you

Published on

MXM logo MxM News

Nancy Pelosi isn’t just walking away from Congress — she’s cashing out of one of the most profitable careers ever built inside it. According to an investigation by the New York Post, the former House Speaker and her husband, venture capitalist Paul Pelosi, turned a modest stock portfolio worth under $800,000 into at least $130 million over her 37 years in office — a staggering 16,900% return that would make even Wall Street’s best blush.

The 85-year-old California Democrat — hailed as the first woman to wield the Speaker’s gavel and infamous for her uncanny market timing — announced this week she will retire when her term ends in January 2027. The Post reported that when Pelosi first entered Congress in 1987, her financial disclosure showed holdings in just a dozen stocks, including Citibank, worth between $610,000 and $785,000. Today, the Pelosis’ net worth is estimated around $280 million — built on trades that have consistently outperformed the Dow, the S&P 500, and even top hedge funds.

The Post found that while the Dow rose roughly 2,300% over those decades, the Pelosis’ reported returns soared nearly seven times higher, averaging 14.5% a year — double the long-term market average. In 2024 alone, their portfolio reportedly gained 54%, more than twice the S&P’s 25% and better than every major hedge fund tracked by Bloomberg.

Pelosi’s latest financial disclosure shows holdings in some two dozen individual stocks, including millions invested in Apple, Nvidia, Salesforce, Netflix, and Palo Alto Networks. Apple remains their single largest position, valued between $25 million and $50 million. The couple also owns a Napa Valley winery worth up to $25 million, a Bay Area restaurant, commercial real estate, and a political data and consulting firm. Their home in San Francisco’s Pacific Heights is valued around $8.7 million, and they maintain a Georgetown townhouse bought in 1999 for $650,000.

The report comes as bipartisan calls grow to ban lawmakers and their spouses from trading individual stocks — a move critics say is long overdue. “What I’ll miss most is how she trades,” said Dan Weiskopf, portfolio manager of an ETF that tracks congressional investments known as “NANC.” He described Pelosi’s trading as “high conviction and aggressive,” noting her frequent use of leveraged options trades. “You only do that if you’ve got confidence — or information,” Weiskopf told the Post.

Among her most striking trades was a late-2023 move that allowed the Pelosis to buy 50,000 shares of Nvidia at just $12 each — less than a tenth of the market price. The $2.4 million investment is now worth more than $7 million. “She’s buying deep in the money and putting up a lot of money doing it,” Weiskopf said. “We don’t see a lot of flip-flopping on her trading activity.”

Republicans blasted Pelosi’s record as proof of Washington’s double standard. “Nancy Pelosi’s true legacy is becoming the most successful insider trader in American history,” said RNC spokesperson Kiersten Pels. “If anyone else had turned $785,000 into $133 million with better returns than Warren Buffett, they’d be retiring behind bars.”

Continue Reading

Business

Ottawa should stop using misleading debt measure to justify deficits

Published on

From the Fraser Institute

By Jake Fuss and Grady Munro

Based on the rhetoric, the Carney government’s first budget was a “transformative” new plan that will meet and overcome the “generational” challenges facing Canada. Of course, in reality this budget is nothing new, and delivers the same approach to fiscal and economic policy that has been tried and failed for the last decade.

First, let’s dispel the idea that the Carney government plans to manage its finances any differently than its predecessor. According to the budget, the Carney government plans to spend more, borrow more, and accumulate more debt than the Trudeau government had planned. Keep in mind, the Trudeau government was known for its recklessly high spending, borrowing and debt accumulation.

While the Carney government has tried to use different rhetoric and a new accounting framework to obscure this continued fiscal mismanagement, it’s also relied on an overused and misleading talking point about Canada’s debt as justification for higher spending and continued deficits. The talking point goes something like, “Canada has the lowest net debt-to-GDP ratio in the G7” and this “strong fiscal position” gives the government the “space” to spend more and run larger deficits.

Technically, the government is correct—Canada’s net debt (total debt minus financial assets) is the lowest among G7 countries (which include France, Germany, Italy, Japan, the United Kingdom and the United States) when measured as a share of the overall economy (GDP). The latest estimates put Canada’s net debt at 13 per cent of GDP, while net debt in the next lowest country (Germany) is 49 per cent of GDP.

But here’s the problem. This measure assumes Canada can use all of its financial assets to offset debt—which is not the case.

When economists measure Canada’s net debt, they include the assets of the Canada Pension Plan (CPP) and the Quebec Pension Plan (QPP), which were valued at a combined $890 billion as of mid-2025. But obviously Canada cannot use CPP and QPP assets to pay off government debt without compromising the benefits of current and future pensioners. And we’re one of the only industrialized countries where pension assets are accounted in such a way that it reduces net debt. Simply put, by falsely assuming CPP and QPP assets could pay off debt, Canada appears to have a stronger fiscal position than is actually the case.

A more accurate measure of Canada’s indebtedness is to look at the total level of debt.

Based on the latest estimates, Canada’s total debt (as a share of the economy) ranked 5th-highest among G7 countries at 113 per cent of GDP. That’s higher than the total debt burden in the U.K. (103 per cent) and Germany (64 per cent), and close behind France (117 per cent). And over the last decade Canada’s total debt burden has grown faster than any other G7 country, rising by 25 percentage points. Next closest, France, grew by 17 percentage points. Keep in mind, G7 countries are already among the most indebted, and continue to take on some of the most debt, in the industrialized world.

In other words, looking at Canada’s total debt burden reveals a much weaker fiscal position than the government claims, and one that will likely only get worse under the Carney government.

Prior to the budget, Prime Minister Mark Carney promised Canadians he will “always be straight about the challenges we face and the choices that we must make.” If he wants to keep that promise, his government must stop using a misleading measure of Canada’s indebtedness to justify high spending and persistent deficits.

Jake Fuss

Director, Fiscal Studies, Fraser Institute

Grady Munro

Policy Analyst, Fraser Institute
Continue Reading

Trending

X